DRUG vs ORYZF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Sell and ORYZF is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DRUG’s FA Score shows that 1 FA rating(s) are green whileORYZF’s FA Score has 1 green FA rating(s).
- DRUG’s FA Score: 1 green, 4 red.
- ORYZF’s FA Score: 1 green, 4 red.
Price Growth
DRUG (@Biotechnology) experienced а +1928.04% price change this week, while ORYZF (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.
Reported Earning Dates
DRUG is expected to report earnings on Aug 28, 2023.
Industries' Descriptions
@Biotechnology (+0.91% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| DRUG | ORYZF | DRUG / ORYZF | |
| Capitalization | 4.85M | 129M | 4% |
| EBITDA | -3.54M | -4.23M | 84% |
| Gain YTD | 1417.483 | 13.529 | 10,477% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 0 | - |
| Total Cash | 6.19M | 10.1M | 61% |
| Total Debt | 14K | 13.4M | 0% |
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
ORYZF and
Correlation & Price change
A.I.dvisor indicates that over the last year, ORYZF has been loosely correlated with CLDI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ORYZF jumps, then CLDI could also see price increases.
| Ticker / NAME | Correlation To ORYZF | 1D Price Change % | ||
|---|---|---|---|---|
| ORYZF | 100% | N/A | ||
| CLDI - ORYZF | 38% Loosely correlated | N/A | ||
| PPBT - ORYZF | 29% Poorly correlated | +1.95% | ||
| DRUG - ORYZF | 25% Poorly correlated | -24.65% | ||
| GNNSF - ORYZF | 24% Poorly correlated | N/A | ||
| IPSC - ORYZF | 21% Poorly correlated | N/A | ||
More | ||||